Magnetic Insight – Magnetic Particle Imaging
Magnetic Insight are pioneering a ground-breaking ultrasensitive, high resolution molecular imaging modality; Magnetic Particle Imaging (MPI). MPI is able to detect magnetic nanoparticles (SPiO) anywhere in the body over great lengths of time and overcome the major deficiencies associated with many other clinical and translational research imaging techniques of sensitivity, resolution and safety.
MPI is an excellent tool for researchers working in areas such as:
- Cancer imaging
- Cell tracking
The workflow involved is no more difficult than optical imaging and the technique generates results in milliseconds.
It is able to carry out similar studies to PET, MRI and CT, but offers superior contrast, sensitivity quantitation and safety. Using safe and flexible tracers, MPI can be used to investigate inflammation, atherosclerotic plaques, and cancers, just to name a few. MPI is the perfect partner for other preclinical imaging modalities
Magnetic Particle Imaging in Research
MPI offers researchers opportunities that have not previously been possible. It is a breakthrough molecular imaging modality that provides nanomolar sensitivity, absolute quantitation, resolution independent of depth and extending the ability to detect tracers from weeks to months. This will accelerate the speed of cell therapy research. It also offers researcher’s absolute quantitation as it is a positive contract modality that is able to measure an absolute linear quantitation of the SPIO nanoparticles independent of tissue depth. This makes data highly reproducible.
Magnetic Particle Imaging in Clinical Applications
MPI is the clinical answer to safe and rapid 3D angiography. It has the benefit that it does not require ionizing (mutagenic) radiation or toxic tracers or contract agents to image intracranial diseases including stroke (stenosis), aneurysm, vasospasms and malformations. As such, there is no need for tracers such as iodine (for CT and fluoroscopy) or gadolinium (for MRI). The low cost and non-toxic super-paramagnetic iron oxide (SPIO) nanoparticles also reduces cost of long term therapy.
Magnetic Insight originated from the leading Magnetic Particle Imaging group based in UC Berkeley (California, USA).
They raised $12 million in funding to accelerate the commercialisation of their technology. Major contributors include:
- Brain Initiative
- California Institute for Regenerative Medicine (CIRM)
- National Institutes of Health (NIH)
- The Keck Foundation
- University of California Discovery grant, jointly supported by General Electric and the State of California